rivastigmine / Generic mfg. - LARVOL DELTA

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study. (PubMed, J Manag Care Spec Pharm) - "All recently approved monoclonal antibodies (eg, aducanumab, lecanemab, and donanemab) for Alzheimer disease (AD) were shown to increase the risks of amyloid-related imaging abnormalities (ARIA) in randomized clinical trials, which can include brain swelling or hemorrhage. Real-world evidence (RWE) studies are critically warranted to evaluate the associated risks of ARIA and health care resource utilization (HRU) with monoclonal treatments compared with existing nonmonoclonal (eg, donepezil, memantine and rivastigmine) treatments...Monoclonal treatment was associated with higher cumulative hazard of ARIA but fewer inpatient visits. This study indicated the potential of RWE, despite its distinct observational design and differences from randomized clinical trials, to serve as a credible proof-of-concept in postapproval assessment and to inform personalized treatment guidelines based on patients' risk factors."

Clinical • HEOR • Journal • Real-world evidence • Retrospective data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dyslipidemia • Hematological Disorders

Comparison table: Drugs for Alzheimer's disease dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Drugs for dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

The ICU environment paradigm as a strategy to enhance the validity of delirium animal models. (PubMed, Clin Sci (Lond)) - "In sepsis + ICU, minocycline and dexmedetomidine reduced IL-1β/IL-6 and improved behavioral performance; rivastigmine improved selected behavioral domains, increased acetylcholine, and reduced AChE activity; dexmedetomidine decreased ROS; and minocycline and rivastigmine attenuated microgliosis. The ICU-like environment worsened behavioral and neurochemical changes, surgery plus anesthesia, and sepsis, supporting its value for enhancing model validity."

Journal • Preclinical • Anesthesia • CNS Disorders • Infectious Disease • Inflammation • Pain • Septic Shock • IL1B • IL6

MEMANTINE IN THE TREATMENT OF DEMENTIA IN HUNGARY (ADPD 2026) - "Of the total cohort, only 13.3% (n=53,070) received anti-dementia medication (memantine, donepezil, or rivastigmine); 12,757 (24.0%) of these were on memantine monotherapy, the group with the highest rate of psychotropic prescriptions. These findings suggest a high proportion of delayed diagnoses, as memantine is indicated in advanced dementia stages. Timely diagnosis—particularly in the era of emerging disease-modifying therapies—along with evidence-based healthcare planning is therefore inevitable."

Alzheimer's Disease • CNS Disorders • Dementia

ANNUAL WELLNESS VISITS INCREASE DEMENTIA MEDICATION PRESCRIBING AMONG U.S. MEDICARE BENEFICIARIES (ADPD 2026) - "However, it remains unclear whether AWVs lead to increased new prescriptions of dementia medications, including N-methyl-D-aspartate receptor antagonists (memantine) and acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine). The number of AWVs received was associated with higher rates of new dementia medication prescriptions. Our findings underscore the important role of AWVs in increasing the prescribing of medications that help manage symptoms of AD/ADRD."

Medicare • Reimbursement • US reimbursement • Alzheimer's Disease • CNS Disorders • Dementia

CENTRAL GAIN, PERIPHERAL RESTRAINT: A CHOLINERGIC STRATEGY FOR PARKINSON DISEASE DEMENTIA (ADPD 2026) - "However, within standard dosing ranges, treatment adherence is limited by peripheral cholinergic ADRs, particularly nausea, diarrhoea, vomiting, tremor and bradyarrhythmia; in a pivotal rivastigmine PDD trial, 17% versus 8% on placebo discontinued because of ADRs, largely cholinergic in origin... Co-administration of a central ChEI with a peripherally selective M2/M3 antagonist represents a rational strategy to widen the therapeutic window in PDD by reducing ADR-driven attrition while maintaining effective NBM/PPN stimulation. Formal mechanistic and clinical evaluation of this combination in PDD is warranted."

Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease

Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review. (PubMed, J Alzheimers Dis) - "At a willingness-to-pay (WTP) threshold of $100,000/QALY, all studies found memantine cost-effective, and more than half reported cost-effectiveness for donepezil, rivastigmine, and galantamine. Under the WTP threshold of $150,000/QALY, value-based prices for aducanumab, lecanemab, and donanemab were estimated below $5,960, $15,700, and $33,700, respectively.ConclusionsTraditional symptom-targeting drugs were consistently cost-effective, whereas anti-amyloid therapies were not. Future independent cost-effectiveness analyses would benefit from head-to-head comparisons using real-world data and greater attention to disparities in dementia research."

HEOR • Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia

Occurrence Characteristics and Associated Factors of Alzheimer's Disease Drugs in Wastewater in China (PubMed, Huan Jing Ke Xue) - "The concentrations and associated factors of four main AD drugs (donepezil, rivastigmine, galantamine, and memantine) and their metabolites in the influent of 210 wastewater treatment plants across 31 Chinese provinces were analyzed. Additionally, correlation analysis also found that socioeconomic factors (such as stress, aging population, level of economic development, and health care services) had a significant positive correlation with the AD prevalence, indicating that socioeconomic factors may influence the occurrence of AD drugs in wastewater by affecting the AD prevalence. These results provide a scientific basis for further understanding of the characteristics of AD drugs in wastewater treatment plants and the development of corresponding control measures."

Journal • Alzheimer's Disease • CNS Disorders

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland. (PubMed, Acta Ophthalmol) - "Our large nested case-control study suggests that certain systemic medications may increase the incidence of surgically treated cataract, but with the possibility of residual confounding."

Journal • Cataract • Diabetes • Metabolic Disorders • Ophthalmology

Rivastigmine attenuates LPS-induced cardiotoxicity via modulation of ER stress, oxidative pathways and apoptosis: Evidence from a rat model. (PubMed, Microvasc Res) - "RIV significantly reduced cardiomyocyte degeneration and improved histological scores compared to LPS-only rats (p < 0.01). Reverse transcription-polymerase chain reaction showed significant downregulation of GRP78, BAX, and HIF-1α, while SIRT1, BCL2 and NRF2 expressions were markedly upregulated (all p < 0.05). Immunohistochemical staining revealed lower IL-6 and Cas-3 scores in the treatment group. These findings highlight RIV's potential as a cardioprotective agent in inflammatory conditions."

IO biomarker • Journal • Preclinical • B Cell Lymphoma • Cardiovascular • Inflammation • Lymphoma • Oncology • BAX • BCL2 • BECN1 • CASP3 • HIF1A • HSPA5 • IL6 • NFE2L2 • SIRT1

AUTHOR (ISPOR 2026) - "Galantamine and rivastigmine were infrequently prescribed (<12% in any given year). ADRD pharmacotherapy in Medicare remained dominated by donepezil and memantine, while combination therapy increased nearly threefold and was largely donepezil-memantine. Antipsychotic use without documented psychiatric disorder persisted, highlighting ongoing safety and prescribing-quality concerns."

Alzheimer's Disease • CNS Disorders • Dementia • Mental Retardation

Speech-induced Platysma Myoclonus in an Older Adult With Cerebral Amyloid Angiopathy: A Diagnostic Pitfall (AAN 2026) - "Memantine was tolerated at 15 mg/day; rivastigmine was not. Speech-induced Platysma Myoclonus is an underrecognized cause of "vocal tics" and speech arrest in older adults. Focused observation during speech tasks and exclusion of bulbar and epileptic etiologies can prevent misattribution to anxiety. Low-dose levetiracetam offered clinically meaningful control."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • Epilepsy • Hematological Disorders • Mood Disorders • Movement Disorders

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Insights into the Molecular Mechanisms of Neurodegenerative Diseases: Exploring Molecular Pathways and the Therapeutic Potential of Rivastigmine. (PubMed, CNS Neurol Disord Drug Targets) - "Emphasis is placed on its mechanism of action, clinical efficacy, and limitations in addressing neurodegeneration. Current advancements, clinical trial outcomes, and potential future directions are discussed to highlight the utility of this approach in the treatment of neurodegenerative disorders."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Discovery of 6,7-Dimethoxyquinazoline-Hydrazide Hybrids as Dual Inhibitors of Acetylcholinesterase and β-Secretase. (PubMed, Biochimie) - "Further in vitro AChE and BACE-1 inhibition activities of both derivatives (3 and 4) revealed that compound 3 exhibited outstanding inhibitory activity against AChE, with IC50 of 299 nM, in comparison to the reference standard, rivastigmine (IC50 of 439 nM)...Post-equilibration analyses revealed stable binding modes supported by key hydrogen bonds and hydrophobic interactions within the active sites. These findings highlight compound 3's strong affinity and specificity toward both targets, supporting its potential as a dual inhibitor."

Journal • Alzheimer's Disease • CNS Disorders • Pain

Zinc-porphyrin complex as multifunctional anti-AD agent: Synthesis, X-ray single crystal analysis and activity study. (PubMed, J Inorg Biochem) - "1-Zn also showed similar cholinesterase inhibition activity as rivastigmine. Consequently, this study demonstrated that 1 and 1-Zn held potential as multifunctional anti-AD agents, meriting further investigation for clinical translation."

Journal • Alzheimer's Disease • CNS Disorders

A physics-informed graph neural network to approximate docking-based binding affinity for DYRK2 in Alzheimer's drug repurposing. (PubMed, Sci Rep) - "Due to the limited number of ligands (n = 4 FDA-approved AD drugs: brexpiprazole, donepezil, galantamine, rivastigmine), the results should be viewed as agreement with computational references rather than generalizable predictive performance. Overall, PhysDual-GCN offers a biologically meaningful and explainable approximation tool for DYRK2 interaction scoring. While the present results are constrained by the small number of compounds and the absence of 3D protein features, the approach establishes a foundation for future large-scale, experimentally validated studies in AD drug repurposing."

Journal • Alzheimer's Disease • CNS Disorders

Assessing Cardiovascular Dysfunction Using Cardiac Strain After Diphenhydramine Overdose. (PubMed, Cureus) - "Diphenhydramine overdose is a dangerous condition that typically leads to symptoms of antimuscarinic toxicity and dysrhythmias. The patient was treated with intravenous fluids and rivastigmine; his symptoms improved appropriately, and he was discharged the following day. This case report highlights the sensitivity of GLS in unveiling LV systolic dysfunction in patients with preserved EF and a normal ECG, showing its potential utility in patients presenting to the ED with substance overdoses."

Journal • Cardiovascular

Hentriacontane alleviates streptozotocin-induced Alzheimer's disease-like conditions in rats: In silico and in vivo investigations revealed the unifying principles. (PubMed, Comput Biol Med) - "In the present investigation, we performed in silico molecular docking, molecular dynamics, MMGBSA, PCA, and FEL analysis of hentriacontane and rivastigmine with acetylcholinesterase (AchE)...Histopathology revealed that the hentriacontane-treated group showed significant restoration of the small pyramidal cells in the CA1 and CA2 regions of the brain. Hentriacontane demonstrated neuroprotective effects by modulation of AchE, leading to improved cognitive functions as evidenced by in silico and in vivo investigations."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Pain • IL1B • IL6 • TNFA

Treatment of animal models of Alzheimer's disease with extracellular vesicles or exosomes and involvement of microRNAs. (PubMed, Neural Regen Res) - "Conventional treatments focus on symptom management through acetylcholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, and the N-methyl-D-aspartate receptor antagonist memantine. However, the past few years have seen the approval of newer agents such as sodium oligomannate, aducanumab, and lecanemab, which show some promise in slowing disease progression...Loading extracellular vesicles and exosomes with microRNA mimics (e.g., miR-22, -29b, -124, -132, -138-5p, -342-5p, -711, and -7670-3p) or antagomirs (e.g., miR-206-antagomir) improved outcomes in animal models of Alzheimer's disease. Supporting results were found in the in vitro cell studies reviewed."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation • Vascular Neurology • MIR206 • MIR22

Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria. (PubMed, Arch Microbiol) - "topiramate, rasagiline, vinpocetine, cilostazol, piracetam, and rivastigmine were tested for both antimalarial and anti-cerebral malaria activity. Overall, these results suggest that combining rivastigmine with α/β-arteether may represent a practical and low-cost adjunct therapy for CM. Further mechanistic and clinical studies will be essential to confirm these findings and assess long-term outcomes."

Journal • Infectious Disease • Malaria

Clinical Observation Study on the Efficacy of Rivastigmine Hydrogen Tartrate Tablets in the Treatment of Moderate Alzheimer's Disease (ChiCTR) - P=N/A | N=3000 | Not yet recruiting | Sponsor: Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital); Guangdong Second Provincial General Hospital (Guangdong Provin

New trial • Alzheimer's Disease • CNS Disorders

Unraveling the neuroprotective potential of Aegle marmelos in Alzheimer's disease: a network pharmacology and molecular docking approach. (PubMed, In Silico Pharmacol) - "Ammijin, O-isopentenylhalfordinol, clionasterol, and fenretinide demonstrated notable binding affinity toward key AD-associated targets, show stronger affinity internal standards used in the study (donepezil and rivastigmine). Further in-vitro and in-vivo investigations are necessary to validate these results and explore their practical applications. The online version contains supplementary material available at 10.1007/s40203-026-00559-x."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Structure-based molecular docking and molecular dynamics simulation of phytoconstituents from Senecio species as potential acetylcholinesterase inhibitors targeting Alzheimer's disease. (PubMed, In Silico Pharmacol) - "By increasing the availability of acetylcholine and thus enhancing cholinergic transmission, acetylcholinesterase inhibitors (AChEIs) like galantamine, donepezil, and rivastigmine are employed to alleviate symptoms. Based on these findings, Senecio species most prominent phytoconstituent can be employed as a therapeutic agent against Alzheimer's disease, but more experimental studies are required to establish its value and therapeutic benefits. The online version contains supplementary material available at 10.1007/s40203-026-00556-0."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Mental Retardation • Pain